Poly (Lactic Acid)Nanofibres as Drug Delivery Systems: Opportunities and Challenges

Authors

  • Akbar Khoddami Department of Textile Engineering, Isfahan University of Technology, Isfahan 84156-8311, Iran
  • Farnaz Fattahi Department of Textile Engineering, Isfahan University of Technology, Isfahan 84156-8311, Iran
  • Ozan Avinc Department of Textile Engineering, Pamukkale University, 20160, Denizli, Turkey
Abstract:

Numerous Scientists have discovered the procedure of nanotechnology, explicitlynanofibers, asdrug delivery systems for transdermal uses. Nanofibers canbe used to deliver drugs and are capable of controlled release for a continued periodof time. Poly (Lactic Acid) (PLA) is the lastly interesting employed synthetic polymer in biomedical application owing to its well categorized biodegradable properties. PLA(−[CH(CH3)COO]n–)is linear biodegradable aliphatic polyester which can be derived from 100% renewable bioresources like rice and wheatthrough fermentation and polymerization. PLA has been accepted by FDA to be applied in biomaterials, such as sutures, bone plates, abdominal mesh, and drug delivery systems. PLA holds stereoisomers,for instancePoly(L-Lactide)(PLLA), Poly(D-Lactide) (PDLA), and Poly(DL-Lactide) (PDLLA). PLGA is a copolymer of PLA and Poly(Glycolic Acid) (PGA) that are most usually used biodegradable synthetic polymers for biomedical applications such as scaffolds and drug delivery systems The objective of this review paper is to highpoint the possibility of PLA nanofibres as drug deliverysubstances and to give full information about the newprogresses about the PLA , PLLA and PLGA nanofibers fabrication as noveldrug delivery systems.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Multiprotein Systems As Targets for Drug Discovery: Opportunities and Challenges

In the past twenty years structural biology has come to play a major role in lead optimization and target identification in the process of drug discovery. Only recently, however, has the development of highthroughput methods of structure determination provided a powerful approach to the screening of fragment binding so that structural biology can now contribute directly to lead discovery. Most ...

full text

Pluronic as nano-carier for drug delivery systems

A common approach for building a drug delivery system is to incorporate the drug within the nanocarrier that results in increased solubility, metabolic stability, and improved circulation time. However, recent developments indicate that selection of polymer nanomaterials can implement more than only inert carrier functions by being biological response modifiers. One representative of such mater...

full text

Nanophase Ceramics for Improved Drug Delivery: Current Opportunities and Challenges

Introduction After more than a decade of research and development, nanotechnology has reshaped the traditional thinking (or lack thereof) of using ceramics for drug delivery. Although drug delivery has been a polymer-dominated field, the blossoming of nanotechnology means that ceramic materials are now showing much promise for numerous drug delivery applications. Typically, nanotechnology is de...

full text

Cancer Therapeutics- Opportunities, Challenges and Advances in Drug Delivery

This review highlights the characteristics of the cancer that provide opportunities for drug delivery carriers to target cancer. These opportunities include EPR effect, high interstitial pressure of tumour, low pH of endosomes of tumor cells, overexpressed receptors, angiogenesis etc. Chemotherapy is one of the most important treatments currently available among the various approaches. The pres...

full text

Kidney-Specific Drug Delivery: Review of Opportunities, Achievements, and Challenges

Kidneys are involved in essential complex procedures that maintain the body in equilibrium and preservethe interior environment necessary for life. Nephritis and nephrosis were ranked among the leading causes of death in all ages in the last global burden of disease assessment of the World Health Organization (WHO). Regarding kidney disease therapeutics, the unfavourable extra-target effects, t...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue 3

pages  130- 140

publication date 2019-09-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023